Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report) shares saw unusually-strong trading volume on Tuesday . 504,555 shares traded hands during mid-day trading, an increase of 195% from the previous session's volume of 171,004 shares.The stock last traded at $27.00 and had previously closed at $26.71.
Analysts Set New Price Targets
LKFT has been the subject of a number of recent analyst reports. Zacks Research upgraded Lakefront Biotherapeutics American Depositary Shares from a "strong sell" rating to a "hold" rating in a report on Monday, June 8th. Royal Bank Of Canada decreased their target price on Lakefront Biotherapeutics American Depositary Shares from $28.00 to $26.00 and set a "sector perform" rating for the company in a research note on Tuesday, August 11th. Weiss Ratings upgraded Lakefront Biotherapeutics American Depositary Shares from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, August 27th. Morgan Stanley cut their price target on Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an "equal weight" rating on the stock in a report on Tuesday, August 11th. Finally, TD Cowen assumed coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, August 21st. They issued a "buy" rating for the company. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and seven have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $30.67.
Read Our Latest Stock Analysis on Lakefront Biotherapeutics American Depositary Shares
Lakefront Biotherapeutics American Depositary Shares Trading Up 4.6%
The firm's 50-day moving average is $28.39 and its 200-day moving average is $29.10. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of -19.81 and a beta of 0.28.
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The biotechnology company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.97) by $1.01. The business had revenue of $15.47 million for the quarter, compared to analyst estimates of $7.29 million. Analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -1.27 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the stock. ABC Arbitrage SA purchased a new stake in Lakefront Biotherapeutics American Depositary Shares in the 1st quarter valued at $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Lakefront Biotherapeutics American Depositary Shares during the 1st quarter worth $248,000. QRG Capital Management Inc. grew its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 21.9% in the 1st quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company's stock worth $591,000 after acquiring an additional 3,535 shares in the last quarter. Finally, Madison Avenue Partners LP grew its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 0.8% in the 4th quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company's stock worth $72,371,000 after acquiring an additional 17,394 shares in the last quarter. Institutional investors own 32.46% of the company's stock.
Lakefront Biotherapeutics American Depositary Shares Company Profile
(
Get Free Report)
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lakefront Biotherapeutics American Depositary Shares, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lakefront Biotherapeutics American Depositary Shares wasn't on the list.
While Lakefront Biotherapeutics American Depositary Shares currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
